Table 1.
Demographics and basic CSF characteristics of the patients.
| CIDP | GBS | IIH | RRMS | |
|---|---|---|---|---|
| Number of patients | 32 (4 A-CIDP) | 26 | 63 | 49 |
| Age (median with range) | 58 (18–78) | 59 (18–83) | 32 (18–76) | 33 (18–55) |
| Female (number/percent) | 6/18.7% | 12/46.2% | 50/79.4% | 33/67.3% |
| Male (number/percent) | 26/81.3% | 14/53.8% | 13/20.6% | 16/32.7% |
| CSF cells (median with range) /μl | 1 (0–12) | 1 (0–37) | 1 (0–5) | 4 (0–58) |
| CSF protein (median with range) mg/l | 1075 (358–4640) | 972 (308–3690) | 345 (115–823) | 431 (152–705) |
| BBBD (number/percent) | 31/96.8% | 23/88.5% | 7/11.1% | 8/16.3% |
| Intrathecal Ig synthesis (number/percent) | 1/1.6% | 0/0 % | 1/1.6% | 30/61.2% |
| OCBs (number/percent) | 4/12.5% | 2/7.7% | 1/1.6% | 43/87.8% |
| Hughes Score (median with range) | 2 (1–4)** Mean: 2.1 |
3 (1–5)** Mean: 3.1 |
||
| Modified Rankin Scale (median with range) | 3 (1–4)* Mean: 2.5 |
4 (1–5)* Mean: 3.6 |
||
| Non-treated patients in the last 3 months (number/percent) | 18/56.2% | 15/57.7% | ||
| Therapy with IVIGs in the last 3 months (number/percent of treated patients) | 8/57.1% | 6/54.5% | ||
| Time between onset of symptoms and sampling (median) days | 485 | 10 |
A-CIDP, Acute onset CIDP; BBBD, blood-brain barrier disruption; CIDP, chronic inflammatory demyelinating polyneuropathy; GBS, Guillain-Barré syndrome; IIH, idiopathic intracranial hypertension; Ig, immunoglobulin; OCB, oligoclonal band; IVIG, intravenous immunoglobulin; RRMS, relapsing remitting multiple sclerosis
*
p < 0.05,
**
p < 0.01 (calculated by Mann-Whitney U-test).